Effects of epidermal growth factor, phorbol myristate acetate, and arachidonic acid on choriogonadotropin secretion by cultured human choriocarcinoma cells.
Epidermal growth factor (EGF) binds specifically (Ka = 4 X 10(9) M-1; 1.3 X 10(11) receptors/mg cellular protein) to JEG-3 cells, which respond in the succeeding 24 h by a 400% increase in hCG secretion without a significant change in cell number. Since JEG-3 cells store less than 2% of the 24-h hCG secretion, a significant increase in hCG in the culture medium reflects increased hCG biosynthesis. It is observed that a tumor promoter, phorbol myristate acetate (PMA), binds specifically to the cells (Ka = 5 X 10(8) M-1; 3.9 X 10(11) receptors/mg), reduces (33%) the affinity but not the number of EGF receptors, and stimulates hCG to the same extent as does EGF. The relative potencies of PMA (100%), phorbol dibutyrate (25%), and nonesterified phorbol (no effect) to stimulate hCG parallel their known tumor-promoting activities. Since phospholipids and fatty acids have been implicated in the mechanism of action of EGF and PMA, the effects of arachidonic acid (AA) and inhibitors of its metabolism were studied. The addition of AA had no effect on basal or PMA-stimulated hCG secretion, but it potentiated the effect of EGF by 200%. Indomethacin (a cyclooxygenase inhibitor) had an effect similar to that of AA. Nordihydroguairetic acid (a cyclooxygenase and lipoxygenase inhibitor) reduced by 90% basal and EGF- or PMA-stimulated hCG secretion. These results indicate that the AA pathway can influence the effects of EGF and PMA on hCG secretion and suggest an intermediary role for the lipoxygenase system.
Ilekis
J
J
Benveniste
R
R
D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology*; D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D002396:Catechols / Q000494:pharmacology; D002478:Cells, Cultured; D002822:Choriocarcinoma / Q000378:metabolism*; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D066246:ErbB Receptors; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D009637:Masoprocol; D015240:Phorbol 12,13-Dibutyrate; D010703:Phorbol Esters / Q000378:metabolism; D010704:Phorbols / Q000494:pharmacology*; D011247:Pregnancy; D011493:Protein Kinase C; D011956:Receptors, Cell Surface / Q000187:drug effects; D011955:Receptors, Drug; D011971:Receptors, Immunologic / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000378:metabolism*
D001095:Arachidonic Acids; D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D002396:Catechols; D006063:Chorionic Gonadotropin; D010703:Phorbol Esters; D010704:Phorbols; D011956:Receptors, Cell Surface; D011955:Receptors, Drug; D011971:Receptors, Immunologic; C083141:phorbol ester binding protein; C027776:phorbol ester receptor; D016718:Arachidonic Acid; D015240:Phorbol 12,13-Dibutyrate; D004815:Epidermal Growth Factor; D009637:Masoprocol; D066246:ErbB Receptors; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate; D007213:Indomethacin